RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
NCT00538343 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2025-05-29
Summary
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
Conditions
Interventions
- DRUG
-
berubicin hydrochloride (RTA 744)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-10-31
- Primary Completion
- 2008-12-01
- Completion
- 2009-01-01
Countries
- United States
Study Locations
More Related Trials
-
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
NCT00397501 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
NCT05522491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
NCT00044525 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337 ·Status: RECRUITING ·Phase: PHASE2
-
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00033514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
NCT01363986 ·Status: TERMINATED ·Phase: PHASE2
-
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
NCT03483012 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03449238 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
NCT02536339 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
NCT00470847 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
NCT00102895 ·Status: TERMINATED ·Phase: PHASE2
-
Sitravatinib in Metastatic Breast Cancer
NCT04123704 ·Status: TERMINATED ·Phase: PHASE2
-
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
NCT01939483 ·Status: WITHDRAWN ·Phase: NA
-
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
NCT02260531 ·Status: COMPLETED ·Phase: PHASE2
-
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
NCT01724606 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
NCT02202746 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
NCT04742153 ·Status: UNKNOWN ·Phase: PHASE2
-
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT05323955 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
NCT03838367 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT04588545 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT03641755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
NCT00003351 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
NCT05566574 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2